Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Is Sinking Today

By Prosper Junior Bakiny – Jun 26, 2020 at 11:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The broader market may be dragging this biotech stock down.

What happened?

Shares of Novavax (NVAX -10.14%) are down by 5.9% as of 11:29 a.m. EDT on Friday -- after plunging by more than 10% earlier today -- and this despite the company not reporting any news. However, we can probably attribute Novavax's slump today to the overall decline of the stock market. With confirmed cases of COVID-19 spiking in several states, renewed fears surrounding the prolonged effects of the pandemic are causing many investors to take their money out of the stock market.

So what

Novavax has been at the forefront of the development of a vaccine for COVID-19. And as a result of its efforts, the company's stock has skyrocketed. Novavax's shares are up by about 1,800% year to date. These returns obviously compare favorably to those of the broader market; for that matter, they compare favorably to the performance of most other companies working on developing vaccines for the coronavirus. For instance, shares of Moderna (MRNA -3.19%) are up by a comparatively mild 207% since the beginning of the year. Now that a second wave of COVID-19 cases seems to be on its way in some states, though, some investors may be choosing to cash out their investments in Novavax. 

Man holding his head in panic, with downward pointing graph on the background.

Image source: Getty Images.

Now what

Novavax's stock will continue to be highly volatile in the short term. A lot of companies are looking to develop vaccines for COVID-19, and it's impossible to know at this point which one will cross the finish line first. But Novavax has another potential catalyst on the way. The biotech company recently reported positive results from a phase 3 clinical trial for NanoFlu, a potential flu vaccine for adults 65 and older. Novavax will seek regulatory approval for this vaccine soon, and if it is approved, the company's stock could see even more gains.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.87 (-10.14%) $-2.13
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$119.69 (-3.19%) $-3.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.